NCT00382733View on ClinicalTrials.gov

Oral Topotecan to Treat Recurrent or Persistent Solid Tumors

PHASE1/PHASE2CompletedINTERVENTIONAL

Enrollment

26

Participants

Timeline

Start Date

November 30, 2006

Primary Completion Date

March 31, 2011

Study Completion Date

March 31, 2011

Conditions

Tumors

Interventions

DRUG

Oral Topotecan

Topotecan will be received in one of the five dose levels:0.25mg/day,0.5mg/day, 0.75mg/day, 1.0mg/day, and 1.25mg/day.

Trial Locations (1)

38120

The West Clinic, Memphis

Sponsors

Collaborators (1)

GlaxoSmithKline

All Listed Sponsors

collaborator

GlaxoSmithKline

INDUSTRY

lead

Accelerated Community Oncology Research Network

OTHER